You are here

SARC009

Active
A Phase 2 Trial of dasatinib in advanced sarcoma
Type of Sarcoma: 
Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)
Drug: 
Dasatinib
Accrual Status: 
Open, Not Accruing
Overall Study Principal Investigator: 

Scott Schuetze, MD, PhD
University of Michigan

For more information about this trial and open sites: